Recent

% | $
Quotes you view appear here for quick access.

Trius Therapeutics, AŞ Message Board

imho_dyodd 7 posts  |  Last Activity: Jul 18, 2016 1:51 AM Member since: Jul 19, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Waiting for earnings call this quarter in August and not in november
    Pls find out what % of nyse listed companies don't conduct earnings call EVERY quarter.
    I bet it is a tiny %

  • imho_dyodd by imho_dyodd Jul 8, 2016 12:10 PM Flag

    http://marketrealist.com/2016/06/akorn-inc-focuses-inorganic-growth-strengthen-business/?utm_source=yahoo&utm_medium=feed

  • imho_dyodd by imho_dyodd Jul 8, 2016 10:16 AM Flag

    should have been tied to share price via option grants. I doubt he would have been compensated anything considering how share price has moved since July 2014 despite stellar financial results.

    It seems nobody cares about share price other than a few posters here.

    The next CEO pay shd be mostly long term (3year, 5year vesting) option grants with a tiny cash component for meeting his day to day expenses.

  • Reply to

    Share price

    by imho_dyodd Jul 7, 2016 10:17 AM
    imho_dyodd imho_dyodd Jul 7, 2016 11:01 AM Flag

    Likely you are right. I still hope that it's a real change.

    But the fact remains, share price is stuck or even went down since 2 years, despite stellar results , cashflow and cash accumulation. Talk about missed opportunity cost for shareholders with all that cash

    The other fact also remains, sun's huge acquisitions and investments (taros solid results and taros negative leverage helps sun lower it's leverage ratio aiding hesee acquisitions)

  • imho_dyodd by imho_dyodd Jul 7, 2016 10:17 AM Flag

    I was expecting share price to go up based on yesterdays news, that taro will put ceo whose responsibilities will be to only focus on taro...

  • Reply to

    Kal stepping down as CEO

    by tomcom808 Jul 6, 2016 5:41 PM
    imho_dyodd imho_dyodd Jul 6, 2016 10:37 PM Flag

    Indeed a surprising move that they say "ceo to solely focus on taro".
    Remains to be seen if it is theatrics( Dec independent dir elections are due - isS or glass lewis may weigh in like they did last time?) or really genuine

    Hoping for quarterly earnings call

    Hoping for inorganic growth

    Hoping for details on novexatin, timeline,study results, why previous study was another phase2a. Why it took 3 years,etc

  • Reply to

    Kal stepping down as CEO

    by tomcom808 Jul 6, 2016 5:41 PM
    imho_dyodd imho_dyodd Jul 6, 2016 9:54 PM Flag

    .Let's get a highly professional and importantly a CEO who cares for ALL shares including independent shareholders. Also hoping maybe they are exploring merger strategies with other public companies and get ceo from the target company to lead taro. Maybe (speculating)